The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact


January 1, 2011
240 Pages - SKU: AH6059416
License type:
Table of Contents Search inside this report Related Reports
Countries covered: Global

In 2010, the therapeutic cancer vaccine market witnessed several key milestones. Dendreon's Provenge (sipuleucel-T) became the first product to reach the market; gaining long-awaited FDA approval for metastatic hormone-refractory prostate cancer. The Cancer Research Institute (CRI) and the Cancer Immunotherapy Consortium (CIC) also proposed much needed criteria to standardize vaccine clinical trials.

Although the major milestones attained in the clinical development of therapeutic cancer vaccines has brought hope and guidance for investors, the market is in its commercial infancy. Arrowhead's The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact, numerous challenges must be overcome to create optimal vaccines on an economical scale. Stakeholders can learn from Provenge's developmental pathway to maximize success in this potentially lucrative market.

With over 1.3 million people having been diagnosed with colorectal cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer or melanoma across the seven major markets in 2010, coupled with unsatisfactory survival rates; vaccines could hold the ability to transform the management of cancer.

This in-depth report provides:
  • An identification and analysis of the major challenges within therapeutic cancer vaccine R&D including clinical trial standardization recommendations , designing optimal vaccines and the lessons learnt from Provenge's development pathway
  • Clinical and commercial analysis of key Phase III oncology vaccine candidates
  • An overview and analysis of the current markets for the treatment of various cancers
  • Insight from key opinion leaders (KOLs) on the future applicability of therapeutic vaccines for the treatment of cancer
  • Sales growth rates to 2020 for key products in development


Additional Information

Report highlights

Traditional cancer clinical trial endpoints are not always applicable in the assessment of cancer vaccines. Lengthy trials allowing full data maturation of measuring immune response is limiting market entry. R&D must establish an effective and consistent way to assess vaccines.

Arrowhead has identified almost 400 clinical trials investigating therapeutic oncology vaccines. Whole-cell vaccines are the most popular design in late-stage development. Arrowhead anticipates a wave of products to reach the market over the coming decade.

The market is set to become highly competitive, especially within the lung cancer and melanoma sectors. By 2020 the market could be worth $8 billion. Top revenue earning candidates include GSK’s MAGE-ASCI-A3, Merck/Oncothyreon’s Stimuvax (BLP25), NovaRX’s Lucanix and Lorus Therapeutics/Zor Pharma’s Virulizin.
1    EXECUTIVE SUMMARY
1.1    Scope of Global Cancer Vaccine Market, 2nd Edition: the Potential Revolution of Oncology Management    
1.2    Methodology of Global Cancer Vaccine Market, 2nd Edition: the Potential Revolution of Oncology Management
1.3    Epidemiology of Cancer in the Seven Major Markets    
1.4    Key Challenges in Therapeutic Cancer Vaccine R&D    
1.5    Therapeutic Cancer Vaccines Pipeline Analysis    
1.6    Therapeutic Cancer Vaccines Market Analysis    
2    THE EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF CANCER 
2.1    Cancer Across the Globe
2.2    Cancer in the US    
2.3    Cancer Survival Rates    
2.4    The Economic Impact of Cancer    
3    INTRODUCTION TO THERAPEUTIC CANCER VACCINES 
3.1    The Immune System and Cancer    
3.2    What are Vaccines?    
3.3    Unmet Needs in Current Cancer Therapy    
3.4    The Basics of Cancer Vaccines    
3.5    Why Therapeutic Cancer Vaccines?    
3.6    Early Efforts of Cancer Vaccines    
3.7    Allogeneic Versus Autologous Vaccines    
3.8    Types of Cancer Vaccines    
3.8.1    Viral Vectors and DNA Vaccines    
3.8.2    Antigen/Adjuvant Vaccines    
3.8.3    Whole-Cell Cancer Vaccines    
3.8.4    Anti-Idiotype Vaccines    
3.8.5    Dendritic Cell Vaccines    
4    VACCINES AND THE COLORECTAL CANCER THERAPEUTIC MARKET 
4.1    Overview of Colorectal Cancer    
4.1.1    Prognosis of Colorectal Cancer    
4.2    Epidemiology of Colorectal Cancer in the Seven Major Markets    
4.3    The Therapeutic Management of Colorectal Cancer    
4.3.1    An Overview of Chemotherapy for Colorectal Cancer    
4.3.2    Amgen’s Vectibix (panitumumab)    
4.3.3    Roche’s Avastin (bevacizumab)    
4.3.4    Clinical Analysis of Arrowhead’s Leading Brand Product in the Colorectal Cancer Market: ImClone/Bristol-Myers Squibb/Merck KgaA’s Erbitux (cetuximab)    
4.4    Revenue Review of Colorectal Cancer Branded Products    
4.5    Unmet Needs in the Colorectal Cancer Market    
4.6    Therapeutic Colorectal Cancer Vaccine Pipeline Analysis    
4.6.1    Vaccinogen’s Oncovax (oncovax-o)    
4.7    Colorectal Cancer Market Commentary    
4.7.1    Financial Forecast of Therapeutic Colorectal Cancer Vaccines    
5    VACCINES AND THE PROSTATE CANCER THERAPEUTIC MARKET 
5.1    Overview of Prostate Cancer    
5.1.1    Prognosis of Prostate Cancer    
5.2    Epidemiology of Prostate Cancer in the Seven Major Markets    
5.3    The Therapeutic Management of Prostate Cancer    
5.3.1    An Overview of Chemotherapy for Prostate Cancer    
5.3.2    Sanofi-Aventis’ Taxotere (docetaxol)    
5.3.3    Clinical Analysis of Arrowhead’s Leading Brand Product in the Prostate Cancer Market: Dendreon’s Provenege (spiuleucel-t)    
5.4    Revenue Review of Prostate Cancer Branded Products    
5.5    Unmet Needs in the Prostate Cancer Market    
5.6    Therapeutic Prostate Cancer Vaccine Pipeline Analysis    
5.6.1    Bavarian Nordic/NCI’s Prostvac    
5.6.2    Northwest Biotherapeutic’s DCVax (dcax- prostate)    
5.7    Prostate Cancer Therapeutics Market Commentary    
5.7.1    Financial Forecast of Therapeutic Prostate Cancer Vaccines    
6    VACCINES AND THE LUNG CANCER THERAPEUTIC MARKET 
6.1    Lung Cancer Overview    
6.1.1    Prognosis of Lung Cancer    
6.2    Epidemiology of Lung Cancer in the Seven Major Markets    
6.3    The Therapeutic Management of Lung Cancer    
6.3.1    An Overview of Chemotherapy for Lung Cancer    
6.3.2    Roche’s Avastin (bevacizumab)    
6.3.3    AstraZeneca’s Iressa (gefitinib)    
6.3.4    Clinical Analysis of Arrowhead’s Leading Brand in the Lung Cancer Market: Roche’s Tarceva (erlotinib)    
6.4    Revenue Review of Lung Cancer Branded Products    
6.5    Unmet Needs in the Lung Cancer Market    
6.6    Therapeutic Lung Cancer Vaccines Pipeline Analysis    
6.6.1    Nova Rx’s Lucanix    
6.6.2    Transgene/Novartis’ TG4010 (mva-muc-il2)    
6.6.3    GlaxoSmithKline’s MAGE-A3-ASCI (GSK1572932A)    
6.6.4    Merck/Oncothyreon’s Stimuvax (BLP25)    
6.7    LUNG CANCER THERAPEUTICS MARKET COMMENTARY    
6.7.1    Financial Forecast of Therapeutic Lung Cancer Vaccines    
7    VACCINES AND THE BREAST CANCER MARKET 
7.1    Breast Cancer Overview    
7.1.1    Prognosis of Breast Cancer    
7.2    Epidemiology of Breast Cancer in the Seven Major Markets    
7.3    The Therapeutic Management of Breast Cancer    
7.3.1    An Overview of Chemotherapy for Breast Cancer    
7.3.2    GlaxoSmithKline’s Tykerb/Tyverb (lapatinib)    
7.3.3    Clinical Analysis of Arrowhead’s Leading Brand in the Breast Cancer Market: Roche’s Herceptin (trastuzumab)    
7.4    Revenue Review of Breast Cancer Branded Products    
7.5    Unmet Needs in the Breast Cancer Market    
7.6    Therapeutic Breast Cancer Vaccine Pipeline Analysis    
7.6.1    Celldex’s CDX1307    
7.7    Breast Cancer Therapeutics Market Commentary    
7.7.1    Financial Forecast of Breast Cancer Therapeutic Vaccines    
8    VACCINES AND THE PANCREATIC CANCER MARKET 
8.1    Pancreatic Cancer Overview    
8.1.1    Prognosis of Pancreatic Cancer    
8.2    Epidemiology of Pancreatic Cancer in the Seven Major Markets    
8.3    The Therapeutic Management of Pancreatic Cancer
8.3.1    An Overview of Chemotherapy for Pancreatic Cancer    
8.3.2    Roche’s Tarceva (erlotinib)    
8.3.3    Clinical Analysis of Arrowhead’s Leading Brand Product in the Pancreatic Cancer Market: Eli-Lilly’s Gemzar (gemcitabine)    
8.4    Revenue Review of Pancreatic Cancer Branded Products    
8.5    Unmet Needs in the Pancreatic Cancer Market    
8.6    Therapeutic Pancreatic Cancer Vaccine Pipeline Analysis    
8.6.1    Kael/GemVax’s GV1001    
8.6.2    Lorus Therapeutic/Zor Pharma’s Virulizin    
8.7    Pancreatic Cancer Therapeutic Market Commentary    
8.7.1    Financial Forecast of Pancreatic Cancer Therapeutic Vaccines    
9    VACCINES AND THE MELANOMA MARKET 
9.1    Melanoma Overview
9.1.1    Prognosis of Melanoma    
9.2    Epidemiology of Melanoma in the Seven Major Markets    
9.3    The Therapeutic Management of Melanoma    
9.3.1    An Overview of Chemotherapy for Melanoma    
9.3.2    Merck/Schering-Plough’s Intron-A (interferon-Alfa 2b)    
9.3.3    Clinical Analysis of Arrowhead’s Leading Brand in the Melanoma Market: Novartis’ Proleukin (aldesleukin)    
9.4    Revenue Review of Melanoma Branded Products    
9.5    Unmet Needs in the Melanoma Market    
9.6    Therapeutic Melanoma Vaccine Pipeline Analysis    
9.6.1    AVAX Tech’s M-Vax (autologous cell vaccine)    
9.6.2    Goshen Health System/NCI’s Gp100 Antigen    
9.6.3    BioVex’s OncoVEX (oncovex gm-csf)    
9.6.4    Antigenic’s Oncophage (vitespen)    
9.7    Melanoma Therapeutics Market Commentary    
9.7.1    Financial Forecast of Melanoma Therapeutic Vaccines    
10    KEY ISSUES IN THERAPEUTIC CANCER VACCINE RESEARCH AND DEVELOPMENT (R&D) 
10.1    Standardization of Cancer Vaccine Clinical Trials    
10.1.1    FDA Proposals of Standardizing Therapeutic Cancer Vaccine Clinical Trials    
10.1.2    CRI and CIC Proposals of Standardizing Therapeutic Cancer Vaccine Clinical Trials    
10.1.3    Autologous Therapeutic Cancer Vaccine Clinical Trial Designs    
10.2    Creating Highly Effective Therapeutic Cancer Vaccines    
10.2.1    Vaccine Designs: Antigen Versus Adjuvant s    
10.2.2    Optimal Disease Stage    
10.2.3    Concomitant Therapies    
10.3    Development of Vaccines with Non-invasive Delivery Routes    
10.4    Lessons to be Learnt from Dendreon's Provenge Development    
11    THERAPEUTIC CANCER VACCINES PIPELINE WATCH 
11.1    Introduction to the Therapeutic Cancer Vaccine Pipeline    
11.1.1    Accentia/BioVest’s BioVaxID    
11.1.2    TVAX Biomedicals’ TVAX (Tvax-Brain-1)    
11.2    Development Status Updates of Phase III Candidate Therapeutic Cancer Vaccines            
12    THERAPEUTIC CANCER VACCINES MARKET IMPACT 
12.1    Therapeutic Cancer Vaccine Potential Promise    
12.2    SWOT Analysis of the Therapeutic Cancer Vaccine Market, 2010    
12.3    Financial Forecast of the Therapeutic Cancer Vaccine Market    
13    BIBLIOGRAPHY
LIST OF TABLES 
Table 1:  Colorectal, Prostate, Lung, Breast, Pancreatic and Melanoma Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Table 2:  Current Late-Stage Therapeutic Cancer Vaccine Pipeline, November 2010 
Table 3:  Worldwide Incidence of Cancer by Geographic Region, 2008
Table 4:  Worldwide Incidence and Deaths Rates by Leading Cancer Type, 2008
Table 5:  Worldwide Number of Cancer Cases for Both Males and Females Combined, 2008 
Table 6:  Estimated Newly Diagnosed Cases and Death Rates in the US by Cancer Type, 2010 
Table 7:  Five-Year Survival Rates for Select Cancers by Stage at Diagnosis, US 2005
Table 8:  The Economic Impact of Cancer in the US, 2010 
Table 9:  Colorectal Cancer Diagnosis and Five-Year Survival Rate by Disease Stage 
Table 10: Crude Incidence Rate of Colorectal Cancer by Gender in the Seven Major Markets, 2010
Table 11: Colorectal Cancer Incidence Forecast in the Seven Major Markets, 2008-2020 
Table 12: Therapeutics Used in Colorectal Cancer 
Table 13: Worldwide Leading Colorectal Cancer Branded Product Revenues ($ millions) 2007- H1 2010 
Table 14: Late-Stage and Phase II Therapeutic Colorectal Cancer Vaccines Pipeline, November 2010
Table 15: Colorectal Cancer Therapeutic Vaccines Revenue Forecast 2015-2020 ($ millions)
Table 16: Prostate Cancer Diagnosis and Five-Year Survival Rate by Disease Stage 
Table 17: Crude Incidence Rate of Prostate Cancer for Males in the Seven Major Markets, 2010
Table 18: Prostate Cancer Incidence Forecast in the Seven Major Markets, 2008-2020 
Table 19: Therapeutics Used in Prostate Cancer 
Table 20: Worldwide Leading Prostate Cancer Branded Product Revenues ($ millions) 2007- H1 2010
Table 21: Late-Stage and Phase II Therapeutic Prostate Cancer Vaccine Pipeline, November 2010 
Table 22: Prostate Cancer Therapeutic Vaccines Revenue Forecast 2010-2020 ($ millions)
Table 23: Lung Cancer Diagnosis and Five-Year Survival Rate by Disease Stage 
Table 24: Crude Incidence Rate of Lung Cancer by Gender (per 100,000) in the Seven Major Markets, 2010 
Table 25: Lung Cancer Incidence Forecast in the Seven Major Markets, 2008-2020 
Table 26: Therapeutics Used in Lung Cancer 
Table 27: Worldwide Leading Lung Cancer Branded Product Revenues ($ millions) 2007-2010 H1 
Table 28: Late-Stage and Phase II Therapeutic Lung Cancer Vaccines Pipeline, November 2010
Table 29: Lung Cancer Therapeutic Vaccines Revenue Forecast 2010-2020 ($ millions)
Table 30: Breast Cancer Diagnosis and Five-Year Survival Rate by Disease Stage
Table 31: Crude Incidence Rate of Breast Cancer for Females in the Seven Major Markets, 2010 
Table 32: Breast Cancer Incidence Forecast in the Seven Major Markets, 2008-2020 
Table 33: Therapeutics Used in Breast Cancer 
Table 34: Worldwide Leading Breast Cancer Branded Product Revenues ($ millions) 2007-2010 H1
Table 35: Late-Stage and Phase II Therapeutic Breast Cancer Vaccines Pipeline, November 2010
Table 36: Pancreatic Cancer Diagnosis and Five-Year Survival Rate by Disease Stage 
Table 37: Crude Incidence Rate of Pancreatic Cancer by Gender in the Seven Major Markets, 2010
Table 38: Pancreatic Cancer Incidence Forecast in the Seven Major Markets, 2008-2020 
Table 39: Therapeutics Used in Pancreatic Cancer 
Table 40: Worldwide Leading Pancreatic Cancer Branded Product Revenues ($ millions) 2007-H1 2010  
Table 41: Late-Stage and Phase II Therapeutic Pancreatic Cancer Vaccines Pipeline, Novemeber 2010
Table 42: Pancreatic Cancer Therapeutic Vaccines Revenue Forecast 2015-2020 ($ millions)
Table 43: Melanoma Cancer Diagnosis and Five-Year Survival Rate by Disease Stage 
Table 44: Crude Incidence Rate of Melanoma by Gender in the Seven Major Markets, 2010
Table 45: Melanoma Incidence Forecast in the Seven Major Markets, 2008-2020 
Table 46: Therapeutics Used in Melanoma  
Table 47: Worldwide Leading Melanoma Branded Product Revenues ($ millions) 2007-H1 2010 
Table 48: Late-Stage and Phase II Therapeutic Melanoma Vaccines Pipeline, November 2010
Table 49: Melanoma Therapeutic Vaccines Revenue Forecast 2010-2020 ($ millions)
Table 50: FDA’s Considerations for Therapeutic Cancer Vaccine Clinical Trials 
Table 51: Challenges and Recommendations for Assessment of Cancer Immunotherapies 
Table 52: The Relative Advantages of Different Therapeutic Cancer Vaccine Designs 
Table 53: Current Late Stage and Phase II Therapeutic Cancer Vaccines Pipeline, November 2010  
Table 54: Development Status Updates of Selected Phase III Therapeutic Cancer Vaccines 
Table 55: Therapeutic Cancer Vaccines Revenue Forecast 2010-2020 ($ millions)
LIST OF FIGURES 
Figure 1:  Colorectal, Prostate, Lung, Breast, Pancreatic and Melanoma Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 2:  Cancer Incidence Forecast in the Seven Major Markets, 2010 and 2020
Figure 3:  Key Challenges in Therapeutic Cancer Vaccine R&D  
Figure 4:  The Late-Stage Therapeutic Cancer Vaccine Pipeline by the Number of Candidates of Different Vaccine Type Design, November 2010 
Figure 5:  Comparison of the Value of the Therapeutic Cancer Vaccine Market, 2010 and 2020 
Figure 6:  Cancer Incidence Worldwide by Geographic Region, 2008 
Figure 7:  Worldwide Number of Cancer Cases for Males and Females Combined, 2008 
Figure 8:  Schematic Diagram of the Production of DNA/Viral Vector Vaccines 
Figure 9:  Schematic Diagram of Antigen/Adjuvant Vaccines Mode of Action 
Figure 10: Schematic Diagram of Whole-Cell Tumor Vaccine Production 
Figure 11: Schematic Diagram of Anti-Idiotype Vaccine Production 
Figure 12: Schematic Diagram of Dendritic Cell Cancer Vaccine Production
Figure 13: The Anatomy of the Human Digestive System 
Figure 14: Colorectal Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 15: OncoVax’s Treatment Schedule
Figure 16: The Anatomy of the Male Reproductive System 
Figure 17: Prostate Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 18: The Anatomy of the Human Respiratory System 
Figure 19: Lung Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 20: The Anatomy of the Human Breast 
Figure 21: Breast Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 22: The Anatomy of the Human Pancreas 
Figure 23: Pancreatic Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 24: The Anatomy of Human Skin 
Figure 25: Melanoma Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 26: The Current Therapeutic Cancer Vaccine Pipeline by the Number of Candidates by Vaccine Type, November 2010
Figure 27: SWOT Analysis of the Therapeutic Cancer Vaccine Market, 2010 
Figure 28: Therapeutic Cancer Vaccines Revenue Forecast 2010-2020 ($ millions)
Figure 29: Total Therapeutic Cancer Vaccine Market Revenue Forecast 2010-2020 ($ millions)

More Cancer Vaccines reports by Arrowhead Publishers

Cancer Vaccines: Measuring Market Potential by Arrowhead Publishers
This brand new report published in October 2004 provides an overview of the emerging market for cancer vaccines and measures their potential impact on a ...
See all reports like this >>

More Global Cancer Vaccines reports

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets by BCC Research
This report provide: An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection ...
Vaccines 2012 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments by Kalorama Information
This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for ...
Human Vaccines by Global Industry Analysts
This report analyzes the worldwide markets for Prophylatic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines. ...
Vaccines Review and Outlook 2010 by PharmaLive Special Reports
The global vaccine market is expected to achieve $34 billion in sales by 2012. With an estimated annual growth rate of 14% during the next ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Cancer Vaccines Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!